DYDC2

Across TCGA pan-cancer cohorts, DYDC2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of DYDC2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DYDC2 RNA is repressed in tumor relative to normal tissue. In most cancer types DYDC2 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

KIRC, LUSC, and LUAD are the cancer types where DYDC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DYDC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	−0.323	<.001	10	view →
LUSC	Female	II,III,IV	−1.945	<.001	8	view →
LUAD	All	III,IV	−1.438	<.001	8	view →
KICH	All	All	−0.339	<.001	8	view →
LIHC	Female	All	+0.924	<.001	7	view →
BRCA	Female	II,III,IV	+0.512	<.001	6	view →
CHOL	All	All	+0.985	.013	3	view →
THCA	All	All	−0.092	.008	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

DYDC2–KIRC

Open the KIRC breakdown →